EUPRAXIA PHARMACEUTICALS INC. Logo

EUPRAXIA PHARMACEUTICALS INC.

Developing targeted, extended-release therapies for GI and musculoskeletal diseases.

EPRX | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
201-2067 CADBORO BAY RD., VICTORIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing targeted therapies through its proprietary Diffusphere™ drug delivery platform. This extended-release technology is engineered to deliver medication precisely to the site of disease, aiming to maximize efficacy and duration while minimizing systemic side effects. The company's clinical pipeline is focused on high-need indications in gastrointestinal and musculoskeletal diseases. Its lead candidate, EP-104GI, is in development for the treatment of Eosinophilic Esophagitis (EoE), with other programs targeting joint pain and related disorders. Eupraxia's patient-centric approach seeks to improve treatment outcomes by providing long-acting, localized therapies for conditions where current standards of care are insufficient.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all EUPRAXIA PHARMACEUTICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EUPRAXIA PHARMACEUTICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EUPRAXIA PHARMACEUTICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.